# APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

> **NCT03175224** · PHASE2 · RECRUITING · sponsor: **Apollomics Inc.** · enrollment: 497 (estimated)

## Conditions studied

- Solid Tumors
- Advanced Cancer
- Renal Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- NSCLC
- Lung Cancer
- Brain Tumor
- Glioblastoma Multiforme
- EGFR Gene Mutation
- MET Amplification
- HGF
- Thyroid Cancer
- Pancreatic Cancer
- Colon Cancer
- MET Alteration
- MET Fusion
- Exon 14 Skipping

## Interventions

- **DRUG:** APL-101 Oral Capsules

## Key facts

- **NCT ID:** NCT03175224
- **Lead sponsor:** Apollomics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-09-27
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 497 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175224, "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03175224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*